Asuragen®
Oncology

QuantideX®

NGS RNA LUNG CANCER KIT*

*For Research Use Only. Not for use in diagnostic procedures.

Coming Soon

Asuragen is pleased to introduce our next NGS solution within the QuantideX® oncology line of assays – QuantideX® NGS RNA Lung Cancer Kit. The assay profiles known RNA fusion transcripts important in human NSCLC.

The targeted NGS panel analyzes >100 known fusion products, MET ex14 skipping events, as well as 3′-5′ imbalances in several key NSCLC fusion genes. The assay is compatible with either total RNA or total nucleic acid (TNA) sample input and is available in a fully kitted configuration – pre-analytical RNA QC, primer library, indexing barcodes, library purification reagents, library quantitation reagents, and sequencing primers. In addition, the kit includes a fusion-positive IVT control and data analysis software (QuantideX® Reporter) for an end-to-end NGS workflow solution for lung cancer samples.

QuantideX®

NGS RNA LUNG CANCER KIT

The QuantideX® NGS RNA Lung Cancer Kit Workflow

A highly integrated NGS-in-a-Box™ kit combining a full set of workflow reagents, controls and software for efficient NGS library preparation.

All library-prep reagents ready out of the box:

- RT-PCR - cDNA preparation from isolated RNA or TNA (FFPE/FNA)
- cDNA quantification and QC
- Gene-Specific PCR
- Dual index barcode tagging
- Bead-based library purification
- Library quantification, normalization and pooling
- Sequencing using MiSeq v2/v3 chemistry*
- Analytics & advanced reporting (QuantideX NGS Reporter suite)

** Not included*



The Advantages of QuantideX: NGS-in-a-Box™





Our unique NGS-in-a-Box approach addresses key laboratory challenges.

- **Labor Utilization** - Optimized workflow minimizes costs and releases valuable resources for other tasks.
- **TAT Pressure** - Improved workflow and simplified assay design significantly reduces time to result, freeing up valuable sequencing time.
- **Results Quality** - Built in IVT control and "Sample-Aware" software solution reduces contamination, error and sample-loss risk.

QuantideX®
4 Steps, 8.5 hrs



Competitor 1
12 Steps, 18 hrs



*For research use only. Not for use in diagnostic procedures.

Note: Product launch date and specifications may be subject to change.

Consistent RNA Fusion Event Detection Down to 5% Sensitivity





The QuantideX NGS RNA Lung Cancer Kit detects fusion events and MET Exon 14 skipping events with as low as 5% sensitivity and across a large dynamic range. The figure represents TNA samples from two representative cell lines with stable expression of two different RNA fusions diluted from a fusion positive 50% of total nucleic acid mass input to a fusion-positive 5% of total nucleic acid mass input.

Empirically Verified Detection Across ALL Panel Content



Confirmed and Tested Variant Detection Across the Full Set of Reportables.
Plot shows fusion detection across all targets in the genomic DNA samples analyzed.

GENE PANEL COMPOSITION

Note: Gene content may differ from final product.

Primary Content:
Clinically Relevant Target Content*

Fusion Target Genes	# Fusions Targeted	5′-3′ Imbalance Detection
ALK	52	✓
ROS1	21	✓
RET	19	✓
FGFR1	1	
FGFR2	1	
FGFR3	7	
NTRK1	3	✓
NTRK3	4	
NRG1	2	
PDGFRA	0	✓

Exon Skipping Targets	# Amplicons
MET exon 14 skipping	3

Optional Content:
Discovery & Emerging Target Content

Gene Expression Targets	
ABCB1	MSLN
BRCA1	PDCD1
CD274	PDCD1LG2
CDKN2A	PTEN
CTLA4	RRM1
ERCC1	TDP1
ESR1	TERT
FGFR1	TLE3
FGFR2	TOP1
FIP1L1	TUBB3
IFNGR	TOP1
ISG15	TUBB3
MET	TYMS

Optional reporting availible for gene expression targets

MAJOR HIGHLIGHTS & ADVANTAGES

- NGS-IN-A-BOX™ KIT CONTAINS ALL REQUIRED MATERIALS FOR AN END-TO-END SAMPLE TO DATA NGS WORKFLOW
- TARGETS 110 KNOWN NSCLC FUSION PRODUCTS, WITH HIGH SENSITIVITY
- 3′-5′ IMBALANCES IN ALK, RET, ROS1, NTRK1, AND PDGFRA
- MET EX14 SKIPPING EVENTS
- mRNA GENE EXPRESSION TARGETS
- OPTIMIZED FOR ILMN SEQUENCERS
- LOW INPUT REQUIREMENT FROM FFPE OR FNA SAMPLES

Vertrieb durch:
VIROTECH Diagnostics GmbH
Löwenplatz 5
D-65428 Rüsselsheim
+49 (0)6142 69090

Asuragen, Inc. | 2150 Woodward St., Suite 100 | Austin, TX 78744 USA

asuragen.com

2500-0600

Note: Product launch date and specifications may be subject to change.
*For Research Use Only. Not for use in diagnostic procedures.